Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Sponsor: Dongkook Pharmaceutical Co., Ltd.
Summary
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Official title: A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Key Details
Gender
MALE
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
161
Start Date
2024-05-30
Completion Date
2026-03-09
Last Updated
2026-08-14
Healthy Volunteers
No
Conditions
Interventions
DKF-MA102
Administered twice at 12-week intervals
Locations (8)
National Cancer Center
Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Asan Medical Center
Seoul, South Korea
Ewha Womans University mokdong Hospital
Seoul, South Korea
Gangnam Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul Saint. Mary's Hospital
Seoul, South Korea